A randomized, double-blind, double-dummy, active-and placebo-controlled, 5-way crossover study of a novel abuse deterrent oxycodone formulation (ELI-200) compared to oxycodone immediate release, oral intact ELI-200, and placebo in healthy, non-dependent recreational opioid users following intranasal administration
Latest Information Update: 03 Sep 2017
Price :
$35 *
At a glance
- Drugs Oxycodone/naltrexone (Primary) ; Oxycodone
- Indications Opioid-related disorders; Pain
- Focus Pharmacodynamics
- 30 Aug 2017 According to an Elite Pharmaceuticals media release, data from this study will be presented at PAINWeek 2017 National Conference.
- 13 Feb 2017 New trial record